Key Takeaways Halozyme will report Q3 2025 earnings on Nov. 3, with estimates pegged at $336.9M for sales and$1.62 for EPS.Royalty gains from Roche, J&J and argenx are expected to lift Halozyme's third-quarter top line.The Elektrofi deal broadens Halozyme's drug delivery tech and reaffirms its 2025 revenue outlook.Halozyme Therapeutics (HALO) is scheduled to report third-quarter 2025 results on Nov. 3, after market close. The Zacks Consensus Estimate for sales and earnings for the third quarter is pegged a ...